682 related articles for article (PubMed ID: 29896812)
1. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
Tan MY; Syngelaki A; Poon LC; Rolnik DL; O'Gorman N; Delgado JL; Akolekar R; Konstantinidou L; Tsavdaridou M; Galeva S; Ajdacka U; Molina FS; Persico N; Jani JC; Plasencia W; Greco E; Papaioannou G; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Aug; 52(2):186-195. PubMed ID: 29896812
[TBL] [Abstract][Full Text] [Related]
2. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
[TBL] [Abstract][Full Text] [Related]
3. Screening for pre-eclampsia at 35-37 weeks' gestation.
Panaitescu A; Ciobanu A; Syngelaki A; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Oct; 52(4):501-506. PubMed ID: 29896778
[TBL] [Abstract][Full Text] [Related]
4. Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.
Francisco C; Wright D; Benkő Z; Syngelaki A; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Nov; 50(5):589-595. PubMed ID: 28556556
[TBL] [Abstract][Full Text] [Related]
5. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial.
Benkő Z; Wright A; Rehal A; Cimpoca B; Syngelaki A; Delgado JL; Tsokaki T; De Alvarado M; Vojtassakova D; Malligiannis Ntalianis K; Chaveeva P; Del Campo A; De Ganzo T; Resta C; Atanasova V; Accurti V; Villalain C; Aguilera J; Dojcinovska D; O'Gorman N; Plasencia W; Zingler E; Dutemeyer V; Alvar B; Casanova MC; Nicolaides KH
Ultrasound Obstet Gynecol; 2021 Feb; 57(2):257-265. PubMed ID: 33142361
[TBL] [Abstract][Full Text] [Related]
7. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
Litwinska M; Syngelaki A; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Sep; 52(3):365-372. PubMed ID: 29943498
[TBL] [Abstract][Full Text] [Related]
8. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE.
Tan MY; Wright D; Syngelaki A; Akolekar R; Cicero S; Janga D; Singh M; Greco E; Wright A; Maclagan K; Poon LC; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Jun; 51(6):743-750. PubMed ID: 29536574
[TBL] [Abstract][Full Text] [Related]
9. Stratification of pregnancy care based on risk of pre-eclampsia derived from uterine artery Doppler at 19-24 weeks' gestation.
Litwinska M; Litwinska E; Lisnere K; Syngelaki A; Wright A; Nicolaides KH
Ultrasound Obstet Gynecol; 2021 Jul; 58(1):67-76. PubMed ID: 33645854
[TBL] [Abstract][Full Text] [Related]
10. Screening for pre-eclampsia by maternal serum glycosylated fibronectin at 11-13 weeks' gestation.
Sokratous N; Bednorz M; Sarli P; Morillo Montes OE; Syngelaki A; Wright A; Nicolaides KH
Ultrasound Obstet Gynecol; 2023 Oct; 62(4):504-511. PubMed ID: 37401855
[TBL] [Abstract][Full Text] [Related]
11. Contingent screening for preterm pre-eclampsia.
Wright D; Gallo DM; Gil Pugliese S; Casanova C; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 May; 47(5):554-9. PubMed ID: 26643929
[TBL] [Abstract][Full Text] [Related]
12. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.
Sokratous N; Wright A; Syngelaki A; Kakouri E; Laich A; Nicolaides KH
Ultrasound Obstet Gynecol; 2024 Jan; 63(1):88-97. PubMed ID: 37724582
[TBL] [Abstract][Full Text] [Related]
13. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 19-23 weeks' gestation.
Sapantzoglou I; Wright A; Arozena MG; Campos RV; Charakida M; Nicolaides KH
Ultrasound Obstet Gynecol; 2021 Jan; 57(1):75-83. PubMed ID: 33142353
[TBL] [Abstract][Full Text] [Related]
14. Impaired placentation in women with chronic hypertension who develop pre-eclampsia.
Panaitescu AM; Akolekar R; Kametas N; Syngelaki A; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Oct; 50(4):496-500. PubMed ID: 28470791
[TBL] [Abstract][Full Text] [Related]
15. Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain.
Cuenca-Gómez D; de Paco Matallana C; Rolle V; Valiño N; Revello R; Adiego B; Mendoza M; Molina FS; Carrillo MP; Delgado JL; Wright A; Santacruz B; Gil MM
Ultrasound Obstet Gynecol; 2023 Oct; 62(4):522-530. PubMed ID: 37099759
[TBL] [Abstract][Full Text] [Related]
16. Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia.
Andrietti S; Carlucci S; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Aug; 50(2):221-227. PubMed ID: 28078815
[TBL] [Abstract][Full Text] [Related]
17. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks' gestation.
Sarno M; Wright A; Vieira N; Sapantzoglou I; Charakida M; Nicolaides KH
Ultrasound Obstet Gynecol; 2021 Apr; 57(4):600-606. PubMed ID: 33073902
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China.
Hu J; Gao J; Liu J; Meng H; Hao N; Song Y; Ma L; Luo W; Sun J; Gao W; Meng W; Sun Y
Ultrasound Obstet Gynecol; 2021 Oct; 58(4):529-539. PubMed ID: 33817865
[TBL] [Abstract][Full Text] [Related]
19. Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment.
Wright D; Tan MY; O'Gorman N; Syngelaki A; Nicolaides KH
BJOG; 2022 Jul; 129(8):1308-1317. PubMed ID: 35015330
[TBL] [Abstract][Full Text] [Related]
20. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]